Below are the database queries which are used to create this measure. These are run against a copy of the BSA prescribing data which we store in Google BigQuery. We're working on making our BigQuery tables publicly available at which point it will be possible to run and modify these queries yourself. But even where code and database queries are not directly useable by others we believe it is always preferable to make them public.
Description | Percentage DOAC items not prescribed as generic rivaroxaban or generic apixaban tablets | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Why it matters | In September 2024 the NHS in England released updated commissioning regulations for DOACs, which state: For patients commencing treatment for atrial fibrillation (AF): subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use the best value DOAC that is clinically appropriate for the patient. Table 1 provides the available DOACs ranked from highest to lowest best value according to the September 2024 and confidential framework prices. If the highest ranked best value DOAC (generic apixaban or generic rivaroxaban) is contraindicated or not clinically appropriate for the specific patient then, subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should then consider the next highest ranked DOAC (edoxaban) and so on until an appropriate treatment is identified.
The NHS England National Medicines Optimisation Opportunities for 2024/25 also identify using best value direct-acting oral anticoagulants as an area for improvement. Please note: OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' and therefore in this case we show the proportion of DOACs which are NOT prescribed as edoxaban or generic apixaban tablets. There are also other oral formulations of generic DOACs recently introduced onto the market. We do not consider these to be as cost-effective, and they are not considered as first-line in this measure. |
||||||||||||||||||
Tags | Cardiovascular system, Standard, Cost Saving, National medicines optimisation opportunities | ||||||||||||||||||
Implies cost savings | No | ||||||||||||||||||
Authored by | richard.croker | ||||||||||||||||||
Checked by | victoria.speed | ||||||||||||||||||
Last reviewed | 2024-10-01 | ||||||||||||||||||
Next review due | 2026-09-16 | ||||||||||||||||||
History | View change history on GitHub → |
SELECT
CAST(month AS DATE) AS month,
practice AS practice_id,
SUM(p.items) AS numerator
FROM hscic.normalised_prescribing p INNER JOIN dmd.vmp vmp ON CONCAT(SUBSTR(p.bnf_code,0,9),'AA', SUBSTR(p.bnf_code,-2), SUBSTR(p.bnf_code,-2)) = vmp.bnf_code -- joins prescribing data to vmp table using generic BNF code
INNER JOIN dmd.vpi AS vpi ON vmp.id = vpi.vmp -- joins vmp to vpi table to get ingredient strengths (strnt_nmrtr_val)
INNER JOIN dmd.ont AS ont ON vmp.id = ont.vmp -- joins vmp to ont table to get formulation codes
INNER JOIN dmd.ontformroute AS route ON ont.form = route.cd -- joins ont table to ontform table to get formulation names
WHERE vpi.ing = 698090000 AND NOT((SUBSTR(p.bnf_code,10,2) ='AA' AND route.descr ='tablet.oral')) --Apixaban (except generic tablets)
OR vpi.ing = 700039002 --Dabigatran etexilate mesilate
OR vpi.ing = 1162278009 --Edoxaban tosilate
OR vpi.ing = 442031002 AND NOT((SUBSTR(p.bnf_code,10,2) ='AA' AND route.descr ='tablet.oral')) --Rivaroxaban (except generic tablets)
GROUP BY month, practice_id
SELECT
CAST(month AS DATE) AS month,
practice AS practice_id,
SUM(p.items) AS denominator
FROM hscic.normalised_prescribing p INNER JOIN dmd.vmp vmp ON CONCAT(SUBSTR(p.bnf_code,0,9),'AA', SUBSTR(p.bnf_code,-2), SUBSTR(p.bnf_code,-2)) = vmp.bnf_code -- joins prescribing data to vmp table using generic BNF code
INNER JOIN dmd.vpi AS vpi ON vmp.id = vpi.vmp -- joins vmp to vpi table to get ingredient strengths (strnt_nmrtr_val)
WHERE vpi.ing IN (698090000,1162278009,700039002,442031002) --Apixaban, dabigatran etexilate mesilate, edoxaban tosilate, rivaroxaban
GROUP BY month, practice_id